Head-to-head · free
Teva Pharmaceutical Industries Limited vs Twist Bioscience
TEVA vs TWST — return on capital, cash generation, margins and balance sheet side by side.
TEVA
4 / 5
measures where TEVA leads
TWST
1 / 5
measures where TWST leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TEVA · FY2025 | TWST · FY2026 |
|---|---|---|
| Revenue | $1.5B | — |
| Net income | $1.4B | (130.2M) |
| Revenue growth (yearly, multi-year) | -44.6% | — |
| Free cash flow | — | (89.0M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | 21.2% | -16.4% |
| Gross margin | 51.8% | 50.7% |
| Operating margin | 22.9% | -36.2% |
| Net debt / EBITDA | 4.19x | 1.64x |
Figures are as reported by each company; latest fiscal year shown.
Where Teva Pharmaceutical Industries Limited's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Twist Bioscience's cash went (FY2026)
- Capital spending
- $47.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free